NVO

Novo Nordisk A/S Form 20-F Summary (Fiscal Year Ended Dec 31, 2019)

Business Context and Reporting Period

This Form 20-F is an annual report for Novo Nordisk A/S, a Danish global healthcare company and world leader in diabetes care, for the fiscal year ended December 31, 2019. The company operates two primary segments: Diabetes and Obesity care (comprising over 84% of sales) and Biopharm (haemophilia, growth disorders, and hormone replacement therapy). Financial statements are prepared in accordance with International Financial Reporting Standards (IFRS) and reported in Danish kroner (DKK). The company employs approximately 43,300 people across 80 countries.

Key Financial Metrics

Debt and Liquidity: No long-term loans were outstanding as of December 31, 2019. Following the implementation of IFRS 16, lease liabilities are recognized as borrowings. Financial resources (cash and cash equivalents plus undrawn committed credit facilities less bank overdrafts) totaled DKK 26,394 million. The company maintains a strong liquidity position with no material restrictions on fund transfers.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased by 9.1% to DKK 122.0 billion. In constant exchange rates, sales grew by 5.6%, driven by volume growth and new product launches.
• Profitability: Operating profit rose 11.1% to DKK 52.5 billion. In constant exchange rates, operating profit grew 5.6%.
• Accounting Changes: The company applied IFRS 16 'Leases' for the first time on January 1, 2019. This resulted in the recognition of right-of-use assets and lease liabilities, impacting the balance sheet but having a neutral impact on free cash flow.
• Product Performance: Ozempic (semaglutide) achieved global sales of DKK 11.2 billion in 2019. Rybelsus (oral semaglutide) received FDA approval in September 2019. Tresiba was added to China's National Reimbursement Drug List effective January 2020.
• Capital Allocation: The company completed a DKK 15 billion share repurchase program in January 2020 and announced a new DKK 17 billion program in February 2020. Total dividends for 2019 were DKK 8.35 per share (a 2% increase).

Guidance, Outlook, Risks, and Contingencies

Outlook: Management expects average prices after rebates in the United States to decline further in 2020 due to legislative changes to Medicare Part D and continued payer pressure. However, market access is expected to remain similar to 2019 levels. Capital expenditure for 2020 is expected to be around DKK 6.5 billion, primarily for capacity expansion.

Risks and Contingencies:

• Public Health Crises: The filing highlights the risk of epidemics, specifically noting the novel coronavirus (nCoV) outbreak in late 2019, which could impact employee safety, production, and sales due to reduced healthcare spending on chronic diseases.
• Brexit: Uncertainty remains regarding the UK's exit from the EU, potentially affecting supply chain logistics, customs duties, and regulatory frameworks.
• Cybersecurity: The company faces risks from IT security breaches and data privacy regulations (GDPR), which could disrupt operations or lead to regulatory penalties.
• Patent Expirations: Key products like NovoLog/NovoRapid, NovoMix, and Levemir have faced or are facing patent expirations, though the company maintains protection via formulation patents or believes biosimilar pathways are limited for complex proteins like NovoSeven.
• Legal Proceedings: Provisions for legal disputes totaled DKK 2,375 million. Significant judgment is required to estimate these liabilities.

Investor Verification Checklist

• US Pricing Pressure: Verify the impact of Medicare Part D legislative changes and PBM rebates on 2020 net sales and margins in the North America segment.
• Patent Cliff Management: Assess the sales trajectory of legacy insulin products (Levemir, NovoLog) as biosimilar competition intensifies in the US and Europe.
• IFRS 16 Impact: Review the reconciliation of lease liabilities and right-of-use assets to understand the true leverage and asset base compared to prior years.
• Iran Sanctions Compliance: Confirm the status of receivables and ongoing business activities with Government of Iran-controlled entities, as disclosed under Section 13(r).
• Share Repurchase Execution: Monitor the execution of the new DKK 17 billion share repurchase program announced in February 2020.